![]() TDFP were well tolerated and provided pain relief in cancer patients equivalent to that achieved with oral morphine. But ten patients reported some skin reactions to the patch, such as erythema, itching, and papules. Patients' pain assessment and side effects were not significantly different during both phases. Assessment of pain, nausea, vomiting, pruritus and somnolence were recorded as visual analogue scale (VAS). TDFP were replaced every 72 hours for 9 days (fentanyl phase). Sixty cancer patients whose pain had been stabilized with oral morphine for at least 48 hours (morphine phase) were switched to TDFP using standard conversion chart for fentanyl dosage. The aim of this study was to investigate the suitability of a dose conversion table from oral morphine to transdermal fentanyl patch (TDFP) and to evaluate the efficacy and safety of TDFP in the treatment of cancer pain. 2Department of Anesthesiology, College of Medicine, Seoul National University, Seoul, Korea. ORAL MORPHINE MILLIGRAM EQUIVALENT CONVERSION TABLEi Updated Opioid (strength in mg except where noted) MME Conversion Factor Buprenorphine, transdermal patch (MCG/HR) 12.6 Buprenorphine, tablet or film 30 Buprenorphine, film (MCG) 0.03 Butorphanol 7 Codeine 0.15 Dihydrocodeine 0.25 Fentanyl, buccal/SL tabet or lozenge/troche (MCG) 0. The Effectiveness of Transdermal Fentanyl Patch in Cancer Pain Patients.ġDepartment of Anesthesiology, College of Medicine, Dankook University, Cheon an, Korea. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |